All In Biotech

Drug Trial Radar · NCT02686658

Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Jun 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 286 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

286

Actual

Start

Dec 15, 2015

Primary completion

Sep 26, 2019

Study completion Apr 23, 2020

Sponsor

Lead sponsor
IVERIC bio, Inc.Industry
Sponsor type
Industry
First posted
Feb 19, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study were to evaluate the safety and efficacy of Zimura intravitreal (IVT) administration when administered in participants with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).

Conditions

  • Geographic Atrophy
  • Dry Age-Related Macular Degeneration

Interventions

  • Avacincaptad PegolDrug

    Avacincaptad Pegol 20 mg/mL solution for intravitreal (IVT) injection

  • ShamOther

    The Sham procedure included the blunt opening of an empty, needleless syringe barrel placed on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Geographic Atrophy as Measured by Fundus AutofluorescenceTime frame: Baseline and 12 months

Locations

78 sites in 7 countries. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Campbell, California

  • Site not named

    Fresno, California

  • Site not named

    Fullerton, California

  • Site not named

    La Jolla, California

  • Site not named

    Mountain View, California

  • Site not named

    Redlands, California

  • Site not named

    Sacramento, California

  • Site not named

    Sacramento, California

  • Site not named

    Santa Ana, California

  • Site not named

    Denver, Colorado

  • Site not named

    Altamonte Springs, Florida

  • Site not named

    Boynton Beach, Florida

  • Site not named

    Melbourne, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Stuart, Florida

  • Site not named

    Winter Haven, Florida

  • Site not named

    Augusta, Georgia

  • Site not named

    Marietta, Georgia

  • Retina Consultants of Hawaii

    ‘Aiea, Hawaii

  • Site not named

    West Des Moines, Iowa

  • Site not named

    Shawnee Mission, Kansas

  • Site not named

    Wichita, Kansas

  • Site not named

    Baltimore, Maryland

  • Site not named

    Chevy Chase, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Springfield, Massachusetts

  • Site not named

    Grand Rapids, Michigan

  • Site not named

    Henderson, Nevada

  • Site not named

    Reno, Nevada

  • Site not named

    Rochester, New York

  • Site not named

    Syracuse, New York

  • Site not named

    Asheville, North Carolina

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Hickory, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Cleveland, Ohio

  • Site not named

    Cleveland, Ohio

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.